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 Introduction 
 Schizophrenia is a heterogeneous disorder with a 
worldwide prevalence of about 1% and a high socioeco-
nomic impact. It is characterized by symptoms such as 
hallucinations or disorganized thinking, loss of goal-di-
rected behaviors, and deterioration in social role func-
tioning. Direct and indirect costs have been estimated at 
about USD 4.3 billion/year in the United States  [1] . 
 There is no doubt that a hereditary component has to 
be assumed  [2] . Additionally, there is major evidence for 
the involvement of an immune process in the pathophys-
iology of the disorder  [3] : in vitro lymphocyte stimulation 
studies showed a reduced production of the proinfl am-
matory, Th1-like cytokines interferon gamma (IFN-  ) or 
interleukin-2 in cells of schizophrenic patients. Elevated 
levels of antibody titers directed against a variety of (au-
to-)antigens were found in serum and cerebrospinal fl uid 
of schizophrenic patients  [4–7] . Based on these fi ndings, 
several authors  [8, 9] concluded that there is a reduced 
cellular immune response in at least a subgroup of schizo-
phrenic patients. This reduced cellular immune response 
was interpreted as being a reduced activation of the Th1 
cells accompanied by a relatively more pronounced activ-
ity of Th2 cells  [9] . 
 Activation of T cells may require a minimum of two 
signals by antigen-presenting cells such as macrophages 
and B cells: the fi rst signal delivered by major histocom-
patibility complex-peptide complex and a second signal 
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 Abstract 
 Objectives: We have previously reported reduced serum 
levels of soluble intercellular adhesion molecule-1 
 (sICAM-1) in schizophrenic patients. A single-nucleotide 
polymorphism (SNP) of the ICAM-1 gene was described 
at position 241. The G ] A SNP results in a nonsynony-
mous amino acid exchange of the ICAM-1 protein, and 
the A allele was shown to be also associated with sev-
eral immunological disorders like rheumatoid arthritis. 
 Methods: We investigated 70 schizophrenic patients and 
128 unrelated healthy control persons regarding the re-
lationship between the serum levels of sICAM-1 and the 
ICAM-1 G214A polymorphism.  Results: We were able to 
replicate our previous fi nding of reduced sICAM-1 levels 
in schizophrenia. Healthy control persons carrying the 
polymorphic A allele showed markedly lower sICAM-1 
serum levels than carriers of the homozygous GG wild 
type (p  ! 0.004). In contrast, no signifi cant difference in 
the sICAM-1 serum levels were seen regarding the G241A 
genotype distribution in schizophrenic patients.  Conclu-
sion: We hypothesize that the biochemical effect of the 
G241A SNP is masked in schizophrenic patients, indicat-
ing a disease-related mechanism leading to reduced lev-
els of sICAM-1 in schizophrenia. 
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delivered by cell surface molecules such as the intercel-
lular adhesion molecule-1 (ICAM-1)  [10] . The adhesion 
molecule ICAM-1 is a transmembrane glycoprotein, 
which belongs to the immunoglobulin superfamily, and 
contains fi ve tandem immunoglobulin-like domains. The 
two ligands of ICAM-1 are the integrins LFA-1 (lympho-
cyte function associated antigen-1, CD11a/CD18) and 
MAC-1 (macrophage-1 antigen, CD11b/CD18)  [11] . 
LFA-1 and MAC-1 are the binding sites for ICAM-1-me-
diated activation of lymphocytes and macrophages, re-
spectively. 
 In a previous investigation  [12] , we demonstrated sig-
nifi cantly decreased serum levels of soluble ICAM-1 
 (sICAM-1) in schizophrenic patients as compared with 
healthy controls. Based on these fi ndings, we have inves-
tigated the gene coding for ICAM-1 as a candidate gene 
for schizophrenia  [13] . The G ] A single-nucleotide poly-
morphism of the ICAM-1 gene located at position 241 in 
exon 4 leads to an amino acid (glycine-to-arginine) re-
placement. This occurs in the binding domain for MAC-
1, a region that is important for the function of the ICAM-
1 protein. We performed a case-control study in 190 
schizophrenic patients and healthy control individuals 
each, but there was no signifi cant difference of the G241A 
genotype distribution between the two groups. 
 In contrast, an increased frequency of the A allele of 
the G241A polymorphism was described in several dis-
orders which are characterized by an infl ammatory pro-
cess: rheumatoid arthritis  [14] , Behçet’s disease  [15] , gi-
ant cell arteritis  [16] , or ulcerative colitis  [17, 18] . All 
these diseases are characterized by increased sICAM-1se-
rum levels  [19–22] . These associations indicate a func-
tionality of the polymorphism in the MAC-1-binding site, 
although experimental data are still lacking  [23] . 
 We reinvestigated our schizophrenic patients and 
healthy controls regarding the relationship between the 
serum levels of sICAM-1 and the G214A polymorphism 
to cover two main objectives: (1) Is the previously report-
ed fi nding of reduced sICAM-1serum levels in schizo-
phrenic patients reproducible? (2) Is the ICAM-1 G241A 
genotype related to sICAM-1 serum levels in schizo-
phrenic patients? 
 Subjects and Methods 
 Subjects 
 A total of 70 Caucasian patients suffering from schizophrenia 
(41 males, 29 females; mean age 31.17  8 10.62 years, age range 
17–63 years) were recruited at the Psychiatric Hospital of the Uni-
versity of Munich, including 21 patients from our fi rst study about 
sICAM-1 in unmedicated and medicated schizophrenic patients 
 [12] who were reinvestigated for the genetic G241A polymorphism. 
All patients were at least 8 weeks free from antipsychotics. 
 In our previous investigation  [12] , we observed that antipsy-
chotic treatment increases the sICAM-1 levels. Therefore, we rein-
vestigated for our examination of a possible association between 
G241A polymorphism and sICAM-1 serum levels only patients 
with a washout period  1 2 months. 
 Diagnoses were established according to the criteria of the 
DSM-IV by two independent experienced psychiatrists. In 50 of 
the patients, paranoid schizophrenia was diagnosed (DSM-IV: 
295.3x), 11 patients carried a diagnosis of disorganized schizophre-
nia (DSM-IV: 295.1x), 1 patient was diagnosed as being catatonic 
schizophrenic (DSM-IV: 295.2x), 2 patients as being undifferenti-
ated schizophrenic (DSM-IV: 295.9x), 1 patient had a schizo-
phreniform disorder (DSM-IV: 295.4x), 2 patients had a residual 
schizophrenia (DSM-IV: 295.6x), and 3 patients had a schizoaffec-
tive disorder (DSM-IV: 295.7x). The mean age at onset was 27.25 
years. Thirty-four of the patients were suffering from their fi rst 
episode of schizophrenia. 
 One hundred and twenty-eight healthy Caucasians from the 
general population (70 males, 58 females; mean age 30.05  8 9.70 
years, age range 18–65 years) were recruited as the control group. 
All controls were screened for past or present psychiatric illnesss by 
interview and by the MMPI-2  [24, 25] . Additionally, they were 
medically examined, including standard laboratory tests. A history 
of a psychosis in a fi rst-degree relative was asked for by interview-
ing the control persons and was considered an exclusion criterion. 
Physical health was evaluated by extensive examinations, including 
blood tests to exclude infectious or infl ammatory diseases in both 
study groups. 
 The study was approved by the local ethics committee, and all 
patients and controls gave their written informed consent after the 
aim of the study had been fully explained. 
 Methods 
 The sICAM-1 serum levels were determined by means of a com-
mercially available double sandwich ELISA (Endogen; Pierce Bio-
technology, Rockford, Ill., USA). Intra- and interassay variances 
were  ! 8%. Measurements were done in duplicate. The paired sam-
ples of 1 patient were always measured within one assay together 
with a set of control samples. The laboratory personnel were blind-
ed regarding the source of the samples. 
 Genomic DNAs from all subjects were prepared from periph-
eral whole-blood cells using the QIAamp system (Qiagen, Hilden, 
Germany). Genotyping of the codon G241A of ICAM-1 was per-
formed by the snapshot method using a PTC-200 thermocycler (MJ 
Research, Watertown, Mass., USA) and a genetic analyzer ABI 
Prism 310 (Applied Biosystems, Foster City, Calif., USA). In the 
fi rst step we carried out a PCR. Forward primer: 5  -ACT CCC CCA 
CAA CTT gTC Ag-3  ; reverse primer: 3  -TCA CAC TgA CTg Agg 
CCT Tg-5  . The PCR was performed with 50 ng DNA in a total 
volume of 25   l containing 0.25   l AmpliTaqGold, 2.5   l 10 ! 
PCR mix, 0.625   l of each primer, and 2.5   l dNTPs for 29 cycles 
of denaturation (95  °  C), annealing (58  °  C), and extension (72  °  C). 
After restriction with SAP and ExoI, a SNAPshot PCR for both 
codons was made. SNAPshot primer: ICAM4-S 5  -CCg TTg TCT 
gTT CCC Tgg AC-3  . The PCR was performed in a total volume 
of 10   l containing 1.0   l template, 1   l SNAPshot primer, and 
 5.0   l SNAPshotReadyReaction Premix, annealing temperature 
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60  °  C. Afterwards, a restriction was performed, and the SNAPshot 
PCR products were sequenced by means of the ABI Prism 310 ge-
netic analyzer. 
 Statistics 
 Statistical analyses were performed using SPSS for windows. 
The results are reported as mean values  8 SD. We used the t test 
for independent samples and the    2  test. Since the differences be-
tween schizophrenic patients and healthy controls regarding serum 
sICAM-1 levels have already been described, we used the one-tailed 
t test. 
 Results 
 The two groups did not differ concerning their age 
 (t = 0.754, d.f. = 196, p = 0.452) or gender (   2  = 0.277, 
d.f. = 1, p = 0.599). The schizophrenic patients showed 
markedly lower serum levels of sICAM-1 (305.51  8 
106.1 ng/ml) than the healthy controls (337.70  8 
79.60 ng/ml; one-tailed t = 2.219, d.f. = 112.25, p = 0.014; 
 table 1 ). 
 The two groups did not differ regarding their ICAM-1 
G241A genotype distribution (   2  = 0.277, d.f. = 1, p = 
0.599;  table 2 ). Both groups were in Hardy-Weinberg 
equilibrium (schizophrenic patients:    2  = 1.127, d.f. = 2, 
p = 0.569; controls:    2  = 0.356, d.f. = 2, p = 0.837). Since 
homozygosity for the polymorphic A allele was extreme-
ly rare, we further combined the AA and GA genotypes 
for comparison with the homozygous wild type (GG). The 
241A allele frequency was 12.9% in the patients and 
10.5% in the controls, while the G allele was found in 
87.1% of the patients and in 89.5% of the controls. 
Statistical comparison of the sICAM-1 serum levels in 
healthy controls unraveled signifi cantly lower levels show-
ing the polymorphic A allele than in those presenting the 
homozygous GG wild type (two-tailed t = 3.027, d.f. = 
54.124, p = 0.004;  table 3 ,  fi g. 1 ). In contrast, no signifi -
cant differences in the sICAM-1 serum levels were seen 
Table 1. Serum levels of sICAM-1 in schizo-
phrenic patients and healthy controls
Group sICAM-1, ng/ml
Schizophrenic (n = 70) 305.518106.06
Controls (n = 128) 337.68879.58
Table 2. Observed genotype distribution of the ICAM-1 G241A 
polymorphism in schizophrenic patients and healthy controls, ad-




GG GA AA GG GA AA
Schizophrenic 52 18 0 53 16 1
Controls 103 23 2 102 24 1
Table 3. Serum levels of sICAM-1 (ng/ml) in relation to the
ICAM-1 G241A genotype in schizophrenic patients and healthy 










 Fig. 1. Serum levels of sICAM-1 in relation to the ICAM-1 G241A 
genotype (wild-type GG versus heterozygous or homozygous A al-
lele) in healthy controls. Outliers are indicated by * and  °. p = 
0.004 . 
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regarding the G241A genotype distribution in schizo-
phrenic patients (two-tailed t = 1.012, d.f. = 68, p = 0.315; 
 table 3 ).
 Discussion 
 Based on the previously reported fi nding of markedly 
reduced sICAM-1 serum levels in schizophrenic patients, 
we investigated the possible relationship between a 
ICAM-1 gene variant and sICAM-1 serum levels in 
schizophrenic patients and in healthy controls. The fi rst 
goal was to confi rm our previous fi nding of reduced 
 sICAM-1 levels in schizophrenia, the second was to pos-
sibly explain the altered sICAM-1 serum levels by the 
ICAM-1 genotype. 
 First of all, we were able to replicate our previous fi nd-
ing of reduced sICAM-1 levels in schizophrenia. Second-
ly, we found a marked relationship between ICAM-1 
G241A genotype and sICAM-1 levels in healthy control 
persons, but not in schizophrenic patients. 
 We report strong evidence of the involvement of the 
ICAM-1 gene G241A polymorphism in the immune 
function. Healthy controls presenting the polymorphic A 
allele showed signifi cantly lower sICAM-1 serum levels 
as compared with homozygous carriers of the GG geno-
type. This is in accordance with results of a recently pub-
lished study, investigating the relationship between 
 sICAM-1 serum levels and ICAM-1 G241A single-nucle-
otide polymorphism  [26] . Moreover, the allele frequen-
cies of our controls are similar to those reported in other 
healthy populations  [27] . 
 The G241A polymorphism leads to an nonsynony-
mous nucleotide exchange that results in a nonconserva-
tive amino acid replacement. Since this occurs in the 
binding domain for MAC-1, a region that is important 
for the adhesion and activation of macrophages and 
monocytes, so it has to be suggested that the function of 
the polymorphism could be related to MAC-1 binding. 
Thus, the affi nity of ICAM-1 to MAC-1 may be reduced, 
and elevated sICAM-1 levels may refl ect an increased ex-
pression of membrane-bound ICAM-1. This hypothesis 
is consistent with the signifi cantly increased frequency of 
the 241A allele in Th1/immune-system-related diseases 
like rheumatoid arthritis  [14] , Behçet’s disease  [15] , giant 
cell arteritis  [16], and ulcerative colitis  [17, 18] . More-
over, elevated sICAM-1 serum levels have been described 
in all of these disorders  [19–22] . However, the direct cor-
relation between ICAM-1 genotype and sICAM serum 
levels has not been studied in these disorders until now. 
 The soluble form of ICAM-1 consists of the complete 
extracellular domain of the adhesion molecule and can 
be found in serum/plasma and cerebrospinal fl uid  [28, 
29] . Principally, there are two ways of sICAM-1 produc-
tion: differential mRNA splicing or proteolytic cleavage 
of the membrane-bound form  [30, 31] . sICAM-1 was con-
sidered a signifi cant and specifi c marker of the course of 
infl ammatory disorders, including multiple sclerosis  [32–
35] . Therefore, sICAM-1 was expected to correlate with 
the expression of the membrane-bound form  [36] . Recent 
results demonstrate an increase of sICAM-1 serum con-
centrations during effective IFN-  therapy of multiple 
sclerosis  [37] . These fi ndings indicate the dependence of 
sICAM-1 level modulation on additional factors. 
 Our fi nding presented herein gives further evidence for 
the functionality of the ICAM-1 G241A polymorphism. 
Moreover, it demonstrates one of the factors that have 
the potency to infl uence the levels of sICAM-1. 
 We did not fi nd any relationship between genotype 
and sICAM-1 levels in the group of schizophrenic pa-
tients. On the other hand, we were able to replicate our 
former fi nding of reduced sICAM-1 serum levels in 
schizophrenic patients. Thus, the reduced sICAM-1 ex-
pression in schizophrenia appears to be caused by a dis-
ease-related process. This process seems to mask the ge-
notype-dependent sICAM-1 expression, as observed in 
healthy persons. One of the most consistent immunolog-
ical fi nding in schizophrenia is a reduced in vitro produc-
tion of the Th1 cytokine IFN-   [38–41] . IFN-  has been 
shown to enhance the cellular ICAM-1 expression and the 
release of sICAM-1 in epithelial cells  [42] . Therefore, low-
er sICAM-1 levels in schizophrenic patients may be re-
lated to a reduced IFN-  signal. 
 There are two possible explanations for this phenom-
enon: The reduced IFN-  signal may either be caused by 
a genetic variant of the IFN-  gene or any other gene re-
lated to the IFN-  signal. On the other hand, there may 
be an active disease process in schizophrenia, character-
ized by a reduced Th1 activation. Redirection of the Th1/
Th2 dysbalance might then serve as a new therapy strat-
egy in schizophrenia. The latter is in accordance with re-
sults of a recent study, investigating the effect of immu-
nomodulation in schizophrenia: based on the Th2 hy-
pothesis, we have carried out a clinical trial with the aim 
to redirect the Th1/Th2 imbalance. Cyclooxygenase-2 in-
hibitors are known to reverse the Th2 predominance by 
inducing the production of Th1-like cytokines and inhib-
iting the production of Th2-like cytokines in noninfl am-
matory conditions  [43, 44] . We, therefore, used the cy-
clooxygenase-2 inhibitor celecoxib in a double-blind, 
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 placebo-controlled study, including a total of 50 schizo-
phrenic patients. Indeed, we could demonstrate the ther-
apeutic effi cacy of cyclooxygenase inhibition  [45] . 
 Further investigation of the mechanism underlying 
the altered immune response in schizophrenic patients 
will thus help to understand the pathophysiology of 
schizophrenia and to fi nd new targets for immunomodu-
lating treatment in schizophrenia. 
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